<SEC-DOCUMENT>0001193125-18-080858.txt : 20180313
<SEC-HEADER>0001193125-18-080858.hdr.sgml : 20180313
<ACCEPTANCE-DATETIME>20180313172256
ACCESSION NUMBER:		0001193125-18-080858
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20180313
ITEM INFORMATION:		Submission of Matters to a Vote of Security Holders
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180313
DATE AS OF CHANGE:		20180313

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CVS HEALTH Corp
		CENTRAL INDEX KEY:			0000064803
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		IRS NUMBER:				050494040
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-01011
		FILM NUMBER:		18687454

	BUSINESS ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895
		BUSINESS PHONE:		4017651500

	MAIL ADDRESS:	
		STREET 1:		ONE CVS DR.
		CITY:			WOONSOCKET
		STATE:			RI
		ZIP:			02895

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CAREMARK CORP
		DATE OF NAME CHANGE:	20070509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS/CAREMARK CORP
		DATE OF NAME CHANGE:	20070322

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CVS CORP
		DATE OF NAME CHANGE:	19970128
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d507907d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C.&nbsp;20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">FORM&nbsp;8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported):&nbsp;March&nbsp;13, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g507907g0313162800614.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>CVS HEALTH CORPORATION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Delaware
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-01011</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">05-0494040</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>One CVS Drive</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Woonsocket, Rhode Island</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>02895</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of Principal Executive Offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code:&nbsp;(401)
<FONT STYLE="white-space:nowrap">765-1500</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9746;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)&nbsp;under</FONT> the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)&nbsp;under</FONT> the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of
this chapter). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Emerging growth company&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;5.07</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Submission of Matters to a Vote of Security Holders. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A special meeting of stockholders (the
&#147;Special Meeting&#148;) of CVS Health Corporation (&#147;CVS Health&#148;) was held on March&nbsp;13, 2018. A total of 795,074,680 shares of CVS Health common stock, out of a total of 1,015,460,751 shares of CVS Health common stock outstanding
and entitled to vote as of the close of business on February&nbsp;5, 2018 (the record date for the Special Meeting), were present in person or represented by proxy. A summary of the voting results for the following proposals, each of which is
described in detail in the joint proxy statement/prospectus of CVS Health and Aetna Inc. (&#147;Aetna&#148;) dated February&nbsp;9, 2018, which was first mailed to CVS Health&#146;s stockholders on or about February&nbsp;12, 2018, is set forth
below: </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Proposal 1. Approval of the Issuance of Shares of CVS Health Common Stock </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health&#146;s stockholders approved the issuance of shares of CVS Health common stock (the &#147;Stock Issuance&#148;) to shareholders of Aetna in the
merger between Aetna and Hudson Merger Sub Corp., a wholly-owned subsidiary of CVS Health Corporation, contemplated by the Agreement and Plan of Merger, dated as of December&nbsp;3, 2017, as it may be amended from time to time, among CVS Health,
Hudson Merger Sub Corp., and Aetna. The proposal was approved by the stockholders by the votes set forth in the table below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:41.55pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;Votes&nbsp;For&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:55.30pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;Votes
Against&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:48.40pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;Abstentions&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:70.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;Broker <FONT
STYLE="white-space:nowrap">Non-Votes&nbsp;&nbsp;</FONT></B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom" ALIGN="center">781,873,839</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">10,539,152</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2,661,689</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">N/A</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Proposal 2. Adjournment of the Special Meeting </U></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because there were sufficient votes at the time of the Special Meeting to approve the Stock Issuance, a vote was not called on the proposal to adjourn the
Special Meeting if necessary to solicit additional proxies if there were not sufficient votes at the time of the Special Meeting to approve the Stock Issuance. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&nbsp;13, 2018, CVS Health issued a press release announcing the results of the
stockholder vote on the Stock Issuance proposal at the Special Meeting. The full text of the press release, a copy of which is attached hereto as Exhibit 99.1, is incorporated herein by reference. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication is for
informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities or the
solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law.
No offer of securities shall be made except by means of a prospectus meeting the requirements of Section&nbsp;10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information and Where to Find It </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection with the proposed transaction between CVS Health Corporation (&#147;CVS Health&#148;) and Aetna Inc. (&#147;Aetna&#148;), on February&nbsp;9, 2018, CVS Health filed with the Securities and Exchange Commission (the &#147;SEC&#148;) an
amendment to the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> that was originally filed on January&nbsp;4, 2018. The registration statement includes a joint proxy statement of CVS Health and Aetna that also constitutes
a prospectus of CVS Health. The registration statement was declared effective by the SEC on February&nbsp;9, 2018, and CVS Health and Aetna commenced mailing the definitive joint proxy statement/prospectus to stockholders of CVS Health and
shareholders of Aetna on or about February&nbsp;12, 2018. INVESTORS AND SECURITY HOLDERS OF CVS HEALTH AND AETNA ARE URGED TO READ THE DEFINITIVE JOINT PROXY </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Investors and
security holders may obtain free copies of the registration statement and the definitive joint proxy statement/prospectus and other documents filed with the SEC by CVS Health or Aetna through the website maintained by the SEC at http://www.sec.gov.
Copies of the documents filed with the SEC by CVS Health are available free of charge within the Investors section of CVS Health&#146;s Web site at http://www.cvshealth.com/investors or by contacting CVS Health&#146;s Investor Relations Department
at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">800-201-0938.</FONT></FONT> Copies of the documents filed with the SEC by Aetna are available free of charge on Aetna&#146;s internet website at http://www.Aetna.com or by
contacting Aetna&#146;s Investor Relations Department at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">860-273-0896.</FONT></FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Statement Regarding Forward-Looking&nbsp;Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Securities Litigation Reform Act of 1995 (the &#147;Reform Act&#148;) provides a safe harbor for forward-looking statements made by or on behalf of
CVS Health or Aetna. This communication may contain forward-looking statements within the meaning of the Reform Act. You can generally identify forward-looking statements by the use of forward-looking terminology such as &#147;anticipate,&#148;
&#147;believe,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;evaluate,&#148; &#147;expect,&#148; &#147;explore,&#148; &#147;forecast,&#148; &#147;guidance,&#148; &#147;intend,&#148; &#147;likely,&#148;
&#147;may,&#148; &#147;might,&#148; &#147;outlook,&#148; &#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;probable,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;view,&#148; or &#147;will,&#148; or the
negative thereof or other variations thereon or comparable terminology. These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond CVS Health&#146;s and Aetna&#146;s control.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this communication regarding CVS Health and Aetna that are forward-looking, including CVS Health&#146;s and Aetna&#146;s projections as to
the closing date for the pending acquisition of Aetna (the &#147;transaction&#148;), the extent of, and the time necessary to obtain, the regulatory approvals required for the transaction, the anticipated benefits of the transaction, the impact of
the transaction on CVS Health&#146;s and Aetna&#146;s businesses, the expected terms and scope of the expected financing for the transaction, the ownership percentages of CVS Health&#146;s common stock of CVS Health stockholders and Aetna
shareholders at closing, the aggregate amount of indebtedness of CVS Health following the closing of the transaction, CVS Health&#146;s expectations regarding debt repayment and its debt to capital ratio following the closing of the transaction, CVS
Health&#146;s and Aetna&#146;s respective share repurchase programs and ability and intent to declare future dividend payments, the number of prescriptions used by people served by the combined companies&#146; pharmacy benefit business, the
synergies from the transaction, and CVS Health&#146;s, Aetna&#146;s and/or the combined company&#146;s future operating results, are based on CVS Health&#146;s and Aetna&#146;s managements&#146; estimates, assumptions and projections, and are
subject to significant uncertainties and other factors, many of which are beyond their control. In particular, projected financial information for the combined businesses of CVS Health and Aetna is based on estimates, assumptions and projections and
has not been prepared in conformance with the applicable accounting requirements of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> relating to pro forma financial information, and the required pro forma adjustments have not been applied and
are not reflected therein. None of this information should be considered in isolation from, or as a substitute for, the historical financial statements of CVS Health and Aetna. Important risk factors related to the transaction could cause actual
future results and other future events to differ materially from those currently estimated by management, including, but not limited to: the timing to consummate the proposed transaction; the risk that a regulatory approval that may be required for
the </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; the risk that a condition to the closing of the proposed transaction may not be
satisfied; the outcome of litigation related to the transaction; the ability to achieve the synergies and value creation contemplated; CVS Health&#146;s ability to promptly and effectively integrate Aetna&#146;s businesses; and the diversion of and
attention of management of both CVS Health and Aetna on transaction-related issues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, this communication may contain forward-looking
statements regarding CVS Health&#146;s or Aetna&#146;s respective businesses, financial condition and results of operations. These forward-looking statements also involve risks, uncertainties and assumptions, some of which may not be presently known
to CVS Health or Aetna or that they currently believe to be immaterial also may cause CVS Health&#146;s or Aetna&#146;s actual results to differ materially from those expressed in the forward-looking statements, adversely impact their respective
businesses, CVS Health&#146;s ability to complete the transaction and/or CVS Health&#146;s ability to realize the expected benefits from the transaction. Should any risks and uncertainties develop into actual events, these developments could have a
material adverse effect on the transaction and/or CVS Health or Aetna, CVS Health&#146;s ability to successfully complete the transaction and/or realize the expected benefits from the transaction. Additional information concerning these risks,
uncertainties and assumptions can be found in CVS Health&#146;s and Aetna&#146;s respective filings with the SEC, including the risk factors discussed in &#147;Item 1.A. Risk Factors&#148; in CVS Health&#146;s and Aetna&#146;s most recent Annual
Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as updated by their Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and future filings with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are cautioned not to place undue reliance on CVS Health&#146;s and Aetna&#146;s forward-looking statements. These forward-looking statements are and will
be based upon management&#146;s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements. Neither CVS Health nor Aetna assumes any duty to update or revise
forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="12%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) The following exhibits are included with this
report: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release, dated March&nbsp;13, 2018, of CVS Health Corporation.</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">INDEX TO EXHIBITS </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B><br><B>No.</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d507907dex991.htm">Press Release, dated March&nbsp;13, 2018, of CVS Health Corporation. </A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CVS HEALTH CORPORATION</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Colleen M. McIntosh</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Colleen M. McIntosh</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President and Corporate Secretary</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Dated:&nbsp;March 13, 2018</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d507907dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g507907g0313163242669.jpg" ALT="LOGO">
<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CVS Health Stockholders Approve Aetna Acquisition </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Transaction expected to close in second half of 2018, subject to regulatory approvals </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>Combined company will focus on remaking the consumer health care experience, </I></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>lowering health care costs </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>WOONSOCKET, R.I., March</B><B></B><B>&nbsp;13, 2018</B> &#150; In a special meeting held today, CVS Health Corporation (NYSE:CVS) stockholders voted to
approve the shares of company stock to be issued in the company&#146;s acquisition of Aetna Inc. (NYSE: AET), one of the nation&#146;s leading diversified health care benefits companies. According to the preliminary results announced at the meeting,
more than 98 percent of the shares voted were in favor of the proposal. The merger is expected to close in the second half of 2018, subject to required regulatory approvals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;When this merger is complete, the combined company will be well-positioned to reshape the consumer health care experience, putting people at the center
of health care delivery to ensure they have access to high-quality, more affordable care where they are, when they need it,&#148; said Larry Merlo, CVS Health president and CEO. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The merger, once complete, will fill an unmet need in the U.S. health care system and presents a unique opportunity to redefine access to high-quality care in
lower cost settings, whether in the community, in the home, or on the go through connected digital health care tools. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;The combination of CVS Health
and Aetna brings together two complementary businesses with an expanded set of unique capabilities to create a new community-based open health care model that is easier to use and less expensive for consumers. We look forward to delivering more
seamlessly coordinated care that ensures consumers have the essential resources to lead healthier lives for themselves and their families,&#148; Merlo continued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;At the same time, our company will benefit from a stronger market position, with the potential to deliver increased value through the development of
innovative new products and services and generate long-term growth opportunities that help produce stronger, more consistent results for shareholders as a uniquely integrated health care company,&#148; Merlo concluded. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About CVS Health </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health is a pharmacy innovation
company helping people on their path to better health. Through its more than 9,800 retail locations, more than 1,100 <FONT STYLE="white-space:nowrap">walk-in</FONT> medical clinics, a leading pharmacy benefits manager with more than 94&nbsp;million
plan members, a dedicated senior pharmacy care business serving more than one million patients per year, expanding specialty </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pharmacy services, and a leading stand-alone Medicare Part D prescription drug plan, the company enables people, businesses and communities to manage health in more affordable and effective ways.
This unique integrated model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at <U>https://www.cvshealth.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contacts: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors: Mike McGuire </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Michael.McGuire@CVSHealth.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">401-770-4050</FONT></FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Media: Joseph Goode </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>Joseph.Goode@CVSHealth.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">401-770-9820</FONT></FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Offer or Solicitation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication is for
informational purposes only and not intended to and does not constitute an offer to subscribe for, buy or sell, the solicitation of an offer to subscribe for, buy or sell or an invitation to subscribe for, buy or sell any securities or the
solicitation of any vote or approval in any jurisdiction pursuant to or in connection with the proposed transaction or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable
law.&nbsp;No offer of securities shall be made except by means of a prospectus meeting the requirements of Section&nbsp;10 of the Securities Act of 1933, as amended, and otherwise in accordance with applicable law. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Additional Information and Where to Find It </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
connection with the proposed transaction between CVS Health Corporation (&#147;CVS Health&#148;) and Aetna Inc. (&#147;Aetna&#148;), on February&nbsp;9, 2018, CVS Health filed with the Securities and Exchange Commission (the &#147;SEC&#148;) an
amendment to the registration statement on Form <FONT STYLE="white-space:nowrap">S-4</FONT> that was originally filed on January&nbsp;4, 2018.&nbsp;The registration statement includes a joint proxy statement of CVS Health and Aetna that also
constitutes a prospectus of CVS Health.&nbsp;The registration statement was declared effective by the SEC on February&nbsp;9, 2018, and CVS Health and Aetna commenced mailing the definitive joint proxy statement/prospectus to stockholders of CVS
Health and shareholders of Aetna on or about February&nbsp;12, 2018.&nbsp;INVESTORS AND SECURITY HOLDERS OF CVS HEALTH AND AETNA ARE URGED TO READ THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED OR THAT WILL BE FILED WITH
THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION.&nbsp;Investors and security holders may obtain free copies of the registration statement and the definitive joint proxy statement/prospectus and
other documents filed with the SEC by CVS Health or Aetna through the website maintained by the SEC at <U>http://www.sec.gov</U>.&nbsp;Copies of the documents filed with the SEC by CVS Health are available free of charge within the Investors section
of CVS Health&#146;s Web site at <U>http://www.cvshealth.com/investors</U> or by contacting CVS Health&#146;s Investor Relations Department at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">800-201-0938.&nbsp;Copies</FONT></FONT>
of the documents filed with the SEC by Aetna are available free of charge on Aetna&#146;s internet website at <U>http://www.Aetna.com</U> or by contacting Aetna&#146;s Investor Relations Department at <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">860-273-0896.</FONT></FONT> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Participants in the Solicitation </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CVS Health, Aetna, their respective directors and certain of their respective executive officers may be considered participants in the solicitation of proxies
in connection with the proposed transaction.&nbsp;Information about the directors and executive officers of CVS Health is set forth in its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017,
which was filed with the SEC on February&nbsp;14, 2018, its proxy statement for its 2017 annual meeting of stockholders, which was filed with the SEC on March&nbsp;31, 2017, and certain of its Current Reports on Form
<FONT STYLE="white-space:nowrap">8-K.&nbsp;Information</FONT> about the directors and executive officers of Aetna is set forth in its Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, which
was filed with the SEC on February&nbsp;23, 2018, its proxy statement for its 2017 annual meeting of shareholders, which was filed with the SEC on April&nbsp;7, 2017, and certain of its Current Reports on Form
<FONT STYLE="white-space:nowrap">8-K.&nbsp;Other</FONT> information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, are contained in the definitive
joint proxy statement/prospectus filed with the SEC and other relevant materials to be filed with the SEC when they become available. </P> <P STYLE="margin-top:0pt;margin-bottom:0pt;page-break-before:always"></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cautionary Statement Regarding Forward-Looking&nbsp;Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Private Securities Litigation Reform Act of 1995 (the &#147;Reform Act&#148;) provides a safe harbor for forward-looking statements made by or on behalf of
CVS Health or Aetna.&nbsp;This communication may contain forward-looking statements within the meaning of the Reform Act.&nbsp;You can generally identify forward-looking statements by the use of forward-looking terminology such as
&#147;anticipate,&#148; &#147;believe,&#148; &#147;can,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;evaluate,&#148; &#147;expect,&#148; &#147;explore,&#148; &#147;forecast,&#148; &#147;guidance,&#148;
&#147;intend,&#148; &#147;likely,&#148; &#147;may,&#148; &#147;might,&#148; &#147;outlook,&#148; &#147;plan,&#148; &#147;potential,&#148; </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;predict,&#148; &#147;probable,&#148; &#147;project,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;view,&#148; or &#147;will,&#148; or the negative thereof or other variations thereon or
comparable terminology.&nbsp;These forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond CVS Health&#146;s and Aetna&#146;s control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Statements in this communication regarding CVS Health and Aetna that are forward-looking, including CVS Health&#146;s and Aetna&#146;s projections as to the
closing date for the pending acquisition of Aetna (the &#147;transaction&#148;), the extent of, and the time necessary to obtain, the regulatory approvals required for the transaction, the anticipated benefits of the transaction, the impact of the
transaction on CVS Health&#146;s and Aetna&#146;s businesses, the expected terms and scope of the expected financing for the transaction, the ownership percentages of CVS Health&#146;s common stock of CVS Health stockholders and Aetna shareholders
at closing, the aggregate amount of indebtedness of CVS Health following the closing of the transaction, CVS Health&#146;s expectations regarding debt repayment and its debt to capital ratio following the closing of the transaction, CVS
Health&#146;s and Aetna&#146;s respective share repurchase programs and ability and intent to declare future dividend payments, the number of prescriptions used by people served by the combined companies&#146; pharmacy benefit business, the
synergies from the transaction, and CVS Health&#146;s, Aetna&#146;s and/or the combined company&#146;s future operating results, are based on CVS Health&#146;s and Aetna&#146;s managements&#146; estimates, assumptions and projections, and are
subject to significant uncertainties and other factors, many of which are beyond their control.&nbsp;In particular, projected financial information for the combined businesses of CVS Health and Aetna is based on estimates, assumptions and
projections and has not been prepared in conformance with the applicable accounting requirements of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> relating to pro forma financial information, and the required pro forma adjustments have not
been applied and are not reflected therein.&nbsp;None of this information should be considered in isolation from, or as a substitute for, the historical financial statements of CVS Health and Aetna.&nbsp;Important risk factors related to the
transaction could cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to:&nbsp;the timing to consummate the proposed transaction; the risk that a
regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated; the risk that a condition to the closing of the proposed transaction may not be
satisfied; the outcome of litigation related to the transaction; the ability to achieve the synergies and value creation contemplated; CVS Health&#146;s ability to promptly and effectively integrate Aetna&#146;s businesses; and the diversion of and
attention of management of both CVS Health and Aetna on transaction-related issues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, this communication may contain forward-looking
statements regarding CVS Health&#146;s or Aetna&#146;s respective businesses, financial condition and results of operations.&nbsp;These forward-looking statements also involve risks, uncertainties and assumptions, some of which may not be presently
known to CVS Health or Aetna or that they currently believe to be immaterial also may cause CVS Health&#146;s or Aetna&#146;s actual results to differ materially from those expressed in the forward-looking statements, adversely impact their
respective businesses, CVS Health&#146;s ability to complete the transaction and/or CVS Health&#146;s ability to realize the expected benefits from the transaction.&nbsp;Should any risks and uncertainties develop into actual events, these
developments could have a material adverse effect on the transaction and/or CVS Health or Aetna, CVS Health&#146;s ability to successfully complete the transaction and/or realize the expected benefits from the transaction.&nbsp;Additional
information concerning these risks, uncertainties and assumptions can be found in CVS Health&#146;s and Aetna&#146;s respective filings with the SEC, including the risk factors discussed in &#147;Item 1.A. Risk Factors&#148; in CVS Health&#146;s and
Aetna&#146;s most recent Annual Reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as updated by their Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and future filings with the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are cautioned not to place undue reliance on CVS Health&#146;s and Aetna&#146;s forward-looking statements.&nbsp;These forward-looking statements are and
will be based upon management&#146;s then-current views and assumptions regarding future events and operating performance, and are applicable only as of the dates of such statements.&nbsp;Neither CVS Health nor Aetna assumes any duty to update or
revise forward-looking statements, whether as a result of new information, future events or otherwise, as of any future date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">XXX </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g507907g0313162800614.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g507907g0313162800614.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  P )D# 2(  A$! Q$!_\0
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; **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g507907g0313163242669.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g507907g0313163242669.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  A 0(# 2(  A$! Q$!_\0
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MY_X$\ WWB/48;FZ@>+2HV#22.,>8!_"OKGU[5] WUC#?Z9<6$JCR9XFB8 =
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MICL;5_B7HOR044451B<G\0_^19D^M>'^#?\ D98_]_\ K117GXG^*C[#)?\
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HJ[=_\?DW^^:** -?2_\ CR7_ 'C6-/\ \?$O^^?YT44 1T444 ?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
